Trials / Unknown
UnknownNCT05616390
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | 200mg IV d1,Q3W |
| DRUG | Bevacizumab | 7.5mg/kg IV d1,Q3W |
| COMBINATION_PRODUCT | Liver Protective Support Therapy | Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy |
Timeline
- Start date
- 2022-11-09
- Primary completion
- 2023-11-01
- Completion
- 2025-11-01
- First posted
- 2022-11-15
- Last updated
- 2023-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05616390. Inclusion in this directory is not an endorsement.